all prices
| price | high | low | % | ||
|---|---|---|---|---|---|
| Dow Jones | 26313 | 26391 | 26083 | -0.1 % | |
| S&P500 | 3117 | 3129 | 3090 | -0.28 % | |
| Nasdaq 100 | 9637 | 9743 | 9576 | -0.64 % | |
| Euro Stoxx 50 | 3254 | 3292 | 3230 | -0.62 % | |
| FTSE 100 | 6332 | 6398 | 6307 | -0.78 % | |
| CAC40 | 4998 | 5052 | 4963 | -0.69 % | |
| DAX | 12415 | 12563 | 12330 | -0.88 % | |
| Hong Kong HSI | 24262 | 24682 | 24221 | -1.95 % | |
| Nikkei 225 | 22761 | 22944 | 22502 | -0.75 % |
Live stock markets prices
- 15 min
- 1H
- 4H
- Daily
| Dow Jones | 26306 | -0.13% |
|---|---|---|
| S&P500 | 3116 | -0.3% |
| Nasdaq 100 | 9635 | -0.66% |
| FTSE 100 | 6332 | -0.78% |
| CAC40 | 4998 | -0.69% |
|---|---|---|
| Nikkei 225 | 22751 | -0.79% |
| Euro Stoxx 50 | 3254 | -0.62% |
| DAX | 12415 | -0.88% |
Latest news
| Uranium Participation Corporation Reports Estimated Net Asset Value, Uranium Sales, Uranium Loans and Share Purchases at May 31, 2020 |
| Clinicians and scientists apply symptom tracking to COVID-19 outpatient care using famotidine |
| ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Conn's, Inc. Investors of Important July 14 Deadline in Securities Class Action - CONN |
| Pond Technologies Announces $1,000,000 Private Placement Offering of Units |
| BGL Announces Merger of Synergy Surgicalists and EA Health Solutions, With a Simultaneous Recapitalization by Enhanced Healthcare Partners |
| NorZinc Announces Results of Annual General Meeting of Shareholders |
| Century Communities Ranks #9 On 2020 Builder 100 List |
| Coronavirus (COVID-19) Update: Daily Roundup |
| Fraser States Organizational Commitment to Anti-Racism and Support for Community |
| TeamChildren and the Andrew Hicks Foundation Donate 25 Laptops to College Bound Chester High Students |
| American Exchange Group partners with Sanrio® for new collection of Hello Kitty® smartwatches for kids |
| Dr. Kiran Mazumdar-Shaw from India named EY World Entrepreneur Of The Year(TM) 2020 |
| DLA Piper advises Iovance Biotherapeutics in its US$604 million common stock offering |
| Pond Technologies Holdings Inc. Announces Filing of 2019 Year-End Audited Financial Statements and MD&A |
| The Province of Buenos Aires Extends Expiration of Invitation Memorandum (as defined below) |
| Mountain Crest Acquisition Corp Announces Pricing of $50 Million Initial Public Offering |
| Proof of Harm To CA's Unborn From Proximity To Oil Wells Proves Need For Barrier Between Wells And People, Says Consumer Watchdog |
| Philadelphia Administrators' Union Protests Racial Injustice, Honors George Floyd With Silent March |
| ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds iAnthus Capital Holdings, Inc. Investors to Contact Firm Before June 15 Deadline in Class Action Seeking Recovery of Investor Losses - ITHUF |
| XLCS Partners advises Nortech Packaging and Tishma Technologies in sale to Intertape Polymer Group |
Uranium Participation Corporation Reports Estimated Net Asset Value, Uranium Sales, Uranium Loans and Share Purchases at May 31, 2020
TSX Trading symbol: U
TORONTO, June 4, 2020 /CNW/ - Uranium Participation Corporation ("UPC") (TSX:U) reports its estimated net asset value at May 31, 2020 was CAD$819.9 million or CAD$6.00 per share. As at May 31, 2020, UPC's uranium investment portfolio consisted of the following: View PDF version.
| (in thousands of Canadian dollars, except quantity amounts) | Â Quantity | Fair Value | |||
| Investments in Uranium: | |||||
| Uranium oxide in concentrates ("U3O8") | Â 15,562,101 Â Â lbs | $ | 729,486 | ||
| Uranium hexafluoride ("UF6") | 600,000 KgU | $ | 84,790 | ||
| $ | 814,276 | ||||
| U3O8 fair value1 per pound: | |||||
| - In Canadian dollars1 | $ | 46.88 | |||
| - In United States dollars | $ | 34.00 | |||
| UF6 fair value1 per KgU: | |||||
| - In Canadian dollars1 | $ | 141.32 | |||
| - In United States dollars | $ | 102.50 | |||
| 1Â Fair values are month-end spot prices published by Ux Consulting Company, LLC, translated at the Bank of | |||||
On the last trading day of May 2020, the common shares of UPC closed on the TSX at a value of CAD$5.12, which represents a 14.67% discount to the net asset value of CAD$6.00 per share.
On April 14, 2020, UPC announced that it had received approval from the TSX to acquire for cancellation, by way of a normal course issuer bid ('NCIB'), up to 12,301,750 common shares of the Corporation, during the period from April 16, 2020 to April 15, 2021.
During May 2020, the Corporation repurchased, for cancellation, 901,864 common shares at a weighted average price of CAD$4.94 for a total purchase price of CAD$4,455,000. Of these shares, 569,514 shares were purchased and held by UPC's broker at the end of May 2020, but had not yet been transferred to UPC for cancellation. Accordingly, the Corporation's estimated net asset value at May 31, 2020 includes a liability of $2,808,000 related to the trades yet to be settled and its issued and outstanding shares has not be reduced for the shares yet to be cancelled. As the trades settle in early June 2020, the shares are cancelled.Â
The share repurchase reported for the month of May 2020 were financed through a combination of existing working capital and the sale of 100,000 pounds of U3O8 at a weighted average purchase price of USD$33.48 per pound, for estimated gross proceeds of CAD$4,713,000. The 100,000 pounds U3O8 sold in May includes a 50,000 pound U3O8 sale transaction entered into on April 30, 2020 and reported in the Company's April 2020 press release.
The net asset value per share of CAD$6.00 has been calculated using a pro forma issued and outstanding share amount of 136,688,311, which reflects the Corporation's issued and outstanding shares at May 31, 2020, less the 569,514 shares which were held for cancellation.
In addition, during the month of May, the Corporation entered into a fully collateralized short-term uranium lending agreement whereby UPC loaned 500,000 pounds of U3O8 to a counterparty for a monthly loan fee of USD$100,000. The total fees to be earned over the term of the arrangement is anticipated to be USD$400,000.
As previously reported (in UPC's news release dated November 14, 2019), UPC has entered into commitments to sell the conversion component contained in 300,000 KgU as UF6 ("Conversion Sale") and to purchase a total of 230,000 pounds of U3O8 ("Uranium Purchase"). The Conversion Sale will result in the exchange of 300,000 KgU as UF6 for 783,856 pounds of U3O8 and cash consideration of USD$6,087,000, and will occur in three equal tranches of 100,000 KgU as UF6 for delivery in January 2020, June 2020, and July 2020. The Uranium Purchase involves the acquisition of three tranches of 100,000 pounds U3O8, 76,300 pounds U3O8, and 53,700 pounds U3O8, for delivery in October 2019, January 2020, and June 2020, respectively, at an average price of USD$26.04. In October 2019, UPC took delivery of the first tranche of 100,000 pounds U3O8. In January 2020, the first Conversion Sale was completed which resulted in an exchange of 100,000 KgU as UF6 for 261,285 pounds of U3O8, and UPC also took delivery of the Uranium Purchase's second tranche of 76,300 pounds U3O8.
Following the completion of the various uranium transactions described above, UPC expects to hold a total of 16,138,372 pounds U3O8, and 400,000 KgU as UF6. The completion of these transaction is also expected to result in a net cash inflow of USD$2,927,000 during the second quarter of fiscal 2021.
About Uranium Participation Corporation
Uranium Participation Corporation is a company that invests substantially all of its assets in uranium oxide in concentrates ("U3O8") and uranium hexafluoride ("UF6") (collectively "uranium"), with the primary investment objective of achieving appreciation in the value of its uranium holdings through increases in the uranium price. UPC provides investors with a unique opportunity to gain exposure to the price of uranium without the resource or project risk associated with investing in a traditional mining company. Additional information about Uranium Participation Corporation is available on SEDAR at www.sedar.com and on UPC's website at www.uraniumparticipation.com.
Caution Regarding Forward-Looking Information
This press release contains certain forward-looking statements and forward-looking information that are based on UPC's current internal expectations, estimates, projections, assumptions and beliefs. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intent", "estimate", "anticipate", "plan", "should", "believe" or "continue" or the negative thereof or variations thereon or similar terminology and include statements with respect to the NCIB and UPC's plans with respect thereto; UPC's investment objectives, its uranium holdings, the transactions entered into with third parties, and agreements with respect thereto.
By their very nature, forward-looking statements involve numerous factors, assumptions and estimates. A variety of factors, many of which are beyond the control of UPC, may cause actual results to differ materially from the expectations expressed in the forward-looking statement. These factors include, but are not limited to, changes in commodity prices and foreign exchange as well as the risk that UPC will not obtain the anticipated benefits of its agreements with third parties. For a description of the principal risks of UPC, see "Risk Factors" in UPC's Annual Information Formed dated May 27, 2020 for the fiscal year ended February 29, 2020, a copy of which is available at www.sedar.com.
These and other factors should be considered carefully, and readers are cautioned not to place undue reliance on these forward-looking statements. Although management reviews the reasonableness of its assumptions and estimates, unusual and unanticipated events may occur which render them inaccurate. Under such circumstances, future performance may differ materially from those expressed or implied by the forward-looking statements. Except where required under applicable securities legislation, UPC does not undertake to update any forward-looking information statement.
SOURCE Uranium Participation Corporation
Clinicians and scientists apply symptom tracking to COVID-19 outpatient care using famotidine
COLD SPRING HARBOR, N.Y., June 4, 2020 /PRNewswire/ -- A patient-reported symptom tracking method used for patients with cancer has now been adapted for patients with COVID-19. Investigating the effect of famotidine on non-hospitalized patients with COVID-19, clinicians at Northwell Health and cancer researchers at Cold Spring Harbor Laboratory (CSHL) developed the method to use in addition to laboratory tests. This outpatient approach addresses the need to care for the majority of COVID-19 patients who do not require hospitalization. The first clinical case series showed that famotidine may help COVID-19 patients with mild to moderately severe symptoms. Next, the team will test the drug in a randomized clinical trial.
Published in the journal GUT, the Northwell-CSHL case series is unique in adapting quantitative tracking of patient reported outcome measures. The methodology is suitable for testing drugs in patients well enough to be managed at home.
The lead author of the study, CSHL Assistant Professor Tobias Janowitz, is a Medical Oncologist and Cancer Researcher, who investigates the whole-body causes and effects of diseases. "The experience of a patient at one point in time is very valuable, but learning about the change in their experience over time is even more important," says Janowitz. "Change indicates if the patients' condition is getting better or worse. A graded symptom score enables the physician and the patient to track symptoms using numbers."
Janowitz and colleagues developed a 4-point scale for six common COVID-19 associated symptoms that patients score every day. Janowitz says, "The experiences from many patients become comparable and can be pooled for analysis."
If a drug speeds recovery, then most patients will report more rapid improvement of symptoms.
The innovations in this study are the product of scientists and physicians who never expected to work on a pandemic. Chief, General Internal Medicine, Northwell Health and Professor at the Feinstein Institutes Joseph Conigliaro, a co-author on the study, says, "What we did is we used our existing tools and talents, but we modified it in ways that were very helpful."
CSHL Professor David Tuveson, Director of the CSHL Cancer Center and another co-author, is interested in the broader implications: "You're trying to scientifically assess a symptom, is what you're really doing."
The early findings of this case series were communicated to co-author Dr. Timothy Wang at Columbia University Medical Center. Dr. Wang and colleagues were also able to find an association between famotidine usage and the improved outcomes of patients hospitalized for COVID-19.
Conigliaro is hopeful: "I think there'll be another surge, but we'll be much better prepared. Hopefully lives will be saved."
About Cold Spring Harbor Laboratory
Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. For more information, visit www.cshl.edu.
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest healthcare provider and private employer in New York State. Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit feinstein.northwell.edu.
View original content to download multimedia:http://www.prnewswire.com/news-releases/clinicians-and-scientists-apply-symptom-tracking-to-covid-19-outpatient-care-using-famotidine-301071098.html
SOURCE Cold Spring Harbor Laboratory
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Conn's, Inc. Investors of Important July 14 Deadline in Securities Class Action - CONN
NEW YORK, June 4, 2020 /PRNewswire/ --Â Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Conn's, Inc. (NASDAQ: CONN) between September 3, 2019 and December 9, 2019, inclusive (the "Class Period") of the important July 14, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Conn's investors under the federal securities laws.
To join the Conn's class action, go to http://www.rosenlegal.com/cases-register-1857.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.
According to the lawsuit, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Conn's business, operations, and prospects. Specifically, defendants failed to disclose that: (1) Conn's was experiencing an increase in first payment defaults and 60-plus day delinquencies; (2) as a result, Conn's was reasonably likely to record an increase to its provision for bad debts; (3) Conn's made certain underwriting adjustments, including tightening its standards for new customers and online applicants; (4) as a result, Conn's same-store sales would be adversely impacted; and (5) as a result of the foregoing, defendants' positive statements about Conn's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1857.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.comÂ
pkim@rosenlegal.comÂ
cases@rosenlegal.comÂ
www.rosenlegal.comÂ
Â
View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-longstanding-and-trusted-firm-reminds-conns-inc-investors-of-important-july-14-deadline-in-securities-class-action--conn-301071064.html
SOURCE Rosen Law Firm, P.A.
Pond Technologies Announces $1,000,000 Private Placement Offering of Units
MARKHAM, ON, June 4, 2020 /CNW/ -Â Pond Technologies Holdings Inc. ("Pond") (TSX.V: POND) (OTC: PNDHF) announced today that it has commenced a non-brokered private placement offering (the "Offering") of up to 4,000,000 units of Pond ("Units") at a purchase price of $0.25 per Unit for aggregate gross proceeds of up to $1,000,000.
Each Unit is comprised of one (1) common share in the capital of Pond ("Common Shares") and one (1) Common Share purchase warrant of Pond ("Warrants"), with each Warrant entitling the holder thereof to purchase one (1) Common Share at a purchase price of $0.25 and expiring on the date that is the earlier of: (i) 30 days after the date on which Pond gives notice to the holders of the Warrants after the Common Shares have traded at a closing price of greater than $1.00 per Common Share for 20 consecutive trading days on the TSX Venture Exchange (the "TSXV") and (ii) the date that is two years after the date that the Warrant is issued. The Common Shares and Warrants comprising the Units will be subject to a statutory hold period which will expire in four months and one day from the date of issuance.
To date, Pond has received subscriptions for an aggregate of 3,645,000 Units ($911,250) under the Offering. Proceeds of the Offering are presently intended to be used for working capital.
The TSXV has conditionally accepted the Offering, requiring Pond to close the Offering and to satisfy the TSXV's final acceptance requirements by no later than June 19, 2020, subject to any application Pond may make to extend such deadline.
About Pond Technologies Holdings Inc.:
Located in Markham, Ontario, Pond is a technology company that provides profitable solutions to the global health and wellness challenges of climate change and nutrition. Pond's proprietary growth platform, including patented advanced photonics, optimizes key growth inputs in order to provide a controlled environment that maximizes the growth of algae and other organisms. This enables industrial emitters to generate new revenue streams from the transformation of underutilized CO2 to valuable algae-based products, such as protein for animal feed and nutraceutical products like Chlorella, Spirulina, and Astaxanthin for human consumption. For more information visit https://www.pondtech.com/.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Pond Technologies Holdings Inc.
BGL Announces Merger of Synergy Surgicalists and EA Health Solutions, With a Simultaneous Recapitalization by Enhanced Healthcare Partners
CLEVELAND, June 4, 2020 /PRNewswire/ -- Brown Gibbons Lang & Company ("BGL") is pleased to announce the merger of Synergy Surgicalists ("Synergy"), one of the nation's top providers of surgicalist staffing to acute care settings, with EA Health Solutions ("EA Health"), the nation's leading provider of specialty physician on-call compensation solutions and physician staffing services. BGL's Healthcare & Life Sciences team served as the exclusive financial advisor to Synergy. The transaction furthers BGL's ongoing commitment to, and experience in, clinical outsourced services. The specific terms of the transaction were not disclosed. Â
Enhanced Healthcare Partners, a leading New York-based private equity firm specializing in middle-market healthcare businesses, facilitated the business merger through a joint recapitalization to form a new company, EA-Synergy. EA-Synergy will offer clinical staffing and performance management services for emergency medicine, emergency department surgical services, and specialty physician on-call services. Its leadership team includes executives from both organizations and will be led by Chief Executive Officer Sriram Iyer, former CEO of EA Health. Industry veteran Bill Sanger, former chairman and CEO of Envision Healthcare, will become chairman of EA-Synergy.
"There exists a tremendous opportunity for innovation in managing the complexities of today's emergency departments," said Sanger. "Our company will leverage significant leadership experience, analytics, and a 'physician-first' culture to drive results for our hospital clients."
Synergy Surgicalists was founded in 2012 in Bozeman, Montana, and provides outsourced surgical staff (or "surgicalists") to approximately 50 hospitals across the U.S. in response to hospital systems who struggle to find doctors willing to do full-time on-call emergency room work, particularly in rural areas.
EA Health was founded in 1992 in San Diego, California, and offers data analytics, revenue-cycle management services and physician staffing services to help hospitals and doctors manage emergency medical programs. In addition to providing outsourced emergency and surgical staffing, EA Health gathers data across a range of issues to help hospitals better coordinate their staffing and manage physician compensation costs.
Driven by the belief that an integrated emergency medicine model offers greater efficiency and efficacy, EA-Synergy will leverage EA Health's technology, including its robust analytical tools, to offer physicians and hospitals valuable insight that will encourage modernization of emergency medicine. EA-Synergy will offer coordinated medical care to patients originating in the emergency department and delivered by front-line emergency physicians and call panel physicians—including surgicalists and specialty physicians—both in-person and via telemedicine.
About Brown Gibbons Lang & Company
Brown Gibbons Lang & Company is a leading independent investment bank and financial advisory firm focused on the global middle market. The firm advises private and public corporations and private equity groups on mergers and acquisitions, divestitures, capital markets, financial restructurings, valuations and opinions, and other strategic matters. BGL has investment banking offices in Chicago, Cleveland, and Philadelphia, and real estate offices in Chicago, Cleveland, Denver, and San Antonio. The firm is also a founding member of Global M&A Partners, enabling BGL to service clients in more than 30 countries around the world. Securities transactions are conducted through Brown, Gibbons, Lang & Company Securities, Inc., an affiliate of Brown Gibbons Lang & Company LLC and a registered broker-dealer and member of FINRA and SIPC. For more information, please visit www.bglco.com.Â
Â
View original content to download multimedia:http://www.prnewswire.com/news-releases/bgl-announces-merger-of-synergy-surgicalists-and-ea-health-solutions-with-a-simultaneous-recapitalization-by-enhanced-healthcare-partners-301071117.html
SOURCE Brown Gibbons Lang & Company
NorZinc Announces Results of Annual General Meeting of Shareholders
NZC-TSX
NORZF-OTCQB
VANCOUVER, BC, June 4, 2020 /CNW/ - NorZinc Ltd. (TSX: NZC; OTCQB: NORZF) (the "Company" or "NorZinc") is pleased to report the voting results of the Annual General Meeting of Shareholders (the "Meeting") held today, June 4, 2020. A total of 212,317,594 common shares were voted, representing the votes attached to 54.47% of all outstanding common shares. Shareholders voted in favour of a motion to fix the number of directors for election at seven and in favour of the election of all director nominees. The percentage of votes cast for each director is as follows:
| Directors | Votes For | Votes Withheld | Outcome |
| Shelley Brown | 179,371,764 (97.68%) | 4,264,440 (2.32%) | Elected |
| Robert J. (Don) MacDonald | 179,289,354 (97.63%) | 4,346,850 (2.37%) | Elected |
| Anita Perry | 179,101,434 (97.53%) | 4,534,770 (2.47%) | Elected |
| Ian R. Ward | 179,358,305 (97.67%) | 4,277,899 (2.33%) | Elected |
| John M. Warwick | 179,377,372 (97.68%) | 4,258,832 (2.32%) | Elected |
| Gary A. Sugar | 179,244,005 (97.61%) | 4,392,199 (2.39%) | Elected |
| Stephen Flewelling | 179,048,757 (97.50%) | 4,587,447 (2.50%) | Elected |
The shareholders voted in favour of all matters brought before the Meeting. The results of the other matters considered at the Meeting including the appointment of auditors, increase to the Company's Stock Option Plan and approval of the unallocated entitlements under the Company's DSU Plan and RSU Plan, are reported in the Report of Voting Results as filed on SEDAR on June 4, 2020.
About NorZinc
NorZinc is a TSX-listed mine development company trading under the symbol "NZC". NorZinc is developing its key project, the 100%-owned high grade zinc-lead-silver Prairie Creek Mine, located in the Northwest Territories. NorZinc also owns projects in Newfoundland that host several zinc-lead-copper-gold-silver deposits.
SOURCE NorZinc Ltd.
Century Communities Ranks #9 On 2020 Builder 100 List
GREENWOOD VILLAGE, Colo., June 4, 2020 /PRNewswire/ -- Century Communities, Inc. (NYSE: CCS), a leading national homebuilder, has been ranked as the ninth-largest in the country on BUILDER's Builder 100 list for the second consecutive year. Century Communities also came in at #1 on BUILDER's list of fastest-growing public builders, an achievement it has maintained for three years running.
"These acknowledgments are a tremendous honor because they reflect the trust homebuyers have put in us for one of life's most important decisions," said Dale Francescon, Co-CEO of Century Communities. "It's also a direct outcome of our ongoing mission to build A Home For Every Dream."
"Our continued status as the fastest-growing public builder really speaks to the quality of our teams," said Rob Francescon, Co-CEO of Century Communities. "From local sales centers and construction sites to the corporate office, our employees are unified in their dedication to providing customers with a best-in-class homebuying experience."
See top builder rankings at BuilderOnline.com.
Century Communities Sees Continued Success With Two-Brand Approach
Much of Century Communities' success can be attributed to a diverse set of offerings, with homes sold under two distinct brands: Century Communities and Century Complete. Operating in locations from coast to coast, the Century Communities brand gives buyers the choice of quick move-in homes and to-be-built homes—offering ground-up personalization—with home types ranging from single-family to townhomes and condos.
Learn more about Century Communities at CenturyCommunities.com.
By contrast, Century Complete has positioned itself as the national leader in online home sales, offering a completely online homebuying experience with streamlined floor plans and finishes—resulting in extra savings that get passed directly to the homebuyer.
Learn more about Century Complete at CenturyCompleteHomes.com.
About Century Communities
Century Communities, Inc. (NYSE: CCS) is a top 10 national homebuilder. Offering new homes under the Century Communities and Century Complete brands, Century is engaged in all aspects of homebuilding—including the acquisition, entitlement and development of land, along with the construction, innovative marketing and sale of quality homes designed to appeal to a wide range of homebuyers. The Colorado-based company operates in 17 states across the U.S., and offers title, insurance and lending services in select markets through its Parkway Title, IHL Insurance Agency, and Inspire Home Loan subsidiaries. To learn more about Century Communities, please visit www.centurycommunities.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/century-communities-ranks-9-on-2020-builder-100-list-301071115.html
SOURCE Century Communities, Inc.
Coronavirus (COVID-19) Update: Daily Roundup
SILVER SPRING, Md., June 4, 2020 /PRNewswire/ --Â The U.S. Food and Drug Administration today continued to take action in the ongoing response to the COVID-19 pandemic:
- Today, the FDA issued a new video resource explaining the different categories of tests in the fight against COVID-19: diagnostic tests and antibody tests. As the video explains, diagnostic tests can tell if the tested person currently is infected. Antibody or serology tests detect if the person's blood contains antibodies to coronavirus. The body produces antibodies when one becomes infected by the virus, and they help the immune system fight off the infection. If an antibody test finds antibodies in the blood, it likely means the person has been previously infected with the virus. Antibody tests do not detect whether a person is currently infected and should not be used to diagnose a current COVID-19 infection. The results from antibody tests can help us better understand questions about exposure to COVID-19.
- On June 3, 2020, the FDA approved an abbreviated new drug application for dexmedetomidine hydrochloride in 0.9% sodium chloride injection (ANDA 209307), indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive-care setting and sedation of non-intubated patients prior to and/or during surgical and other procedures. The most common side effects of dexmedetomidine hydrochloride injection are hypotension, bradycardia and dry mouth. This drug is listed in the FDA Drug Shortage Database. The FDA recognizes the increased demand for certain products during the COVID-19 public health emergency, and we remain deeply committed to facilitating access to medical products to help address critical needs of the American public.
- As part of FDA's effort to protect consumers, the agency issued warning letters to operators of four websites (www.roidsmall.net, www.emedkit.com, www.4nrx.md and www.chloroquineonline.com) that market unapproved and misbranded COVID-19 products. There are currently no FDA-approved drugs to prevent or treat COVID-19. Consumers concerned about COVID-19 should consult with their health care provider. Consumers can visit BeSafeRx to learn about how to safely buy medicine online.
- Today, the FDA announced that on Tuesday, June 9, 12:00 pm – 1:00 pm ET, the FDA will launch a webinar series on Respirators for Health Care Personnel Use during COVID-19 Pandemic. The webinar will provide FDA information and answer questions about emergency use authorizations (EUAs) for respirators, importing respirators, and overall FDA actions to help ensure that health care personnel on the front lines have the necessary supplies of respirators to meet the demand. Hear from speakers, including Stephen M. Hahn, MD, Commissioner of Food and Drugs at the FDA; Jeffrey E. Shuren, MD, JD, Director of the Center for Devices and Radiological Health (CDRH) at the FDA; William H. Maisel, MD, MPH, Director, Office of Product Evaluation and Quality (OPEQ) at CDRH; and Suzanne Schwartz, MD, MBA, Director, Office of Strategic Partnerships and Technology Innovation (OST) at CDRH. We encourage all interested stakeholders to join. Registration is not necessary.
- Today, the FDA issued a letter to clinical laboratory staff and health care providers about a safety risk with using transport media and SARS-CoV-2 testing platforms that are not compatible. There is a risk of exposure to harmful cyanide gas when certain transport media are used with an incompatible testing platform or laboratory process that uses bleach.
- Today, the FDA publicly posted test performance data from four more antibody, or serology, test kits on open.fda.gov from its independent performance validation study effort with the National Institutes of Health's (NIH) National Cancer Institute (NCI). These results are among the first to come from a collaborative effort by the FDA, NIH, Centers for Disease Control and Prevention (CDC) and Biomedical Advanced Research and Development Authority (BARDA). Additional performance data will be made available as the FDA reviews and determines if any further actions are appropriate for those test kits prior to publication.
- Testing updates:
- During the COVID-19 pandemic, the FDA has worked with more than 400 test developers who have already submitted, or said they will be submitting, EUA requests to the FDA for tests that detect the virus or antibodies to the virus.
- To date, the FDA has authorized 120 tests under EUAs, which include 104 molecular tests, 15 antibody tests, and 1 antigen test.
Additional Resources:
- FAQs on Testing for SARS-CoV-2
- Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)
- Coronavirus Disease 2019 (COVID-19)
Media Contact:Â Lee.Herring@fda.hhs.gov, 240-402-6386
Consumer Inquiries: 888-INFO-FDA
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
View original content to download multimedia:http://www.prnewswire.com/news-releases/coronavirus-covid-19-update-daily-roundup-301071112.html
SOURCE U.S. Food and Drug Administration
Fraser States Organizational Commitment to Anti-Racism and Support for Community
MINNEAPOLIS, June 4, 2020 /PRNewswire/ -- Fraser — a Minnesota-based nonprofit that provides lifespan services for healthcare, housing, education, and employment to children, teens, adults, and families facing autism, mental health issues, and special needs — has made an organizational commitment to fight racism in all forms and support the Black, Indigenous, and People of Color (BIPOC) clients and staff it serves.
Black, indigenous, and people of color have experienced deep and prolonged trauma from systemic racism and its entrenched damaging effects on housing, education, socioeconomic status, healthcare, and employment over a lifetime. Fraser is committed to supporting its staff, clients, and community with resources to help them at every stage of life and to process the shock, grief, and fear they face in the aftermath of George Floyd's murder in Minneapolis and the ongoing trauma they experience from centuries of systemic abuse.
Diane S. Cross said, "Fraser was founded in 1945 during the Great Depression to serve children and adults with special needs, with the belief that all individuals have the right to live work learn and play as inclusive members of our society. It is clearer than ever before that this right has not been upheld for people of color."
As a result, Fraser is establishing a new anti-racism initiative to help the organization look inward, learn, enact change, and stand beside its communities of color. The new group will work on ongoing, action-based items for change that combats racism.
"We are eager to work in collaboration with our staff and community to overcome racism in all of its forms," said Diane S. Cross, Fraser President and CEO. "In so doing, we aim to deliver the best healthcare and support available to our clients."Â
Fraser has also launched the Fraser Hope Line, a free call-in service that puts the community in touch with a mental health professional. While the Fraser Hope Line is not a crisis line, it does provide immediate and ongoing resources to help individuals and families manage mental health issues.
The Fraser Hope Line can help with anxiety, depression, grief, and trauma. It is an open hand to help children, teens, adults, and families develop stronger mental health and relationships for a healthier life. The line is answered Monday through Friday, 7 a.m. – 7 p.m., CT. Call 612-446-HOPE (4673) or email fraserhopeline@fraser.org.
| Contact: | Nancy Baldrica |
| Vice President, Chief Marketing & Development Officer |
Â
View original content:http://www.prnewswire.com/news-releases/fraser-states-organizational-commitment-to-anti-racism-and-support-for-community-301071109.html
SOURCE Fraser
TeamChildren and the Andrew Hicks Foundation Donate 25 Laptops to College Bound Chester High Students
CHESTER, Pa., June 4, 2020 /PRNewswire/ --Â TeamChildren and the Andrew Hicks Foundation have been partnering since the Coronavirus to provide free laptops to families in the City of Chester PA. Now over 400 laptops are empowering the educational future of literally hundreds of kids. By Special request from the Chester Upland School district 25 college bound graduates will be surprised when they are handed a great refurbished laptop loaded with amazing learning programs and links.
For the past 23 years, even before it was called the digital divide, Robert Toporek, a decorated Vietnam Veteran, has been living his life beyond the call of duty to make a difference. Often times by the seat of his pants, generous donations of technology equipment from companies like SAP, SEI, Wawa, Acme Markets, Sanofi Aventis, and original QVC, Toporek gathers volunteers to wipe off the hard drives, reinstall operating systems and as far as he is concerned loads hundreds of dollars' worth of learning programs and links.
** A number of students have been selected to meet with and talk to the media at 11 am. **
Where: Stem Academy Chester PA Auditorium
1100 W 10th St
Chester PA 19013
Contacts:
Robert Toporek 484-744-1868, 241154@email4pr.com
Nicole Lasorda 610-475-0765, nicole.lasorda@buchananpr.com
Links:
Andrew Hicks Foundation - https://www.andrewlhicksjrfoundation.org/
TeamChildren - http://www.teamchildren.org/
View original content:http://www.prnewswire.com/news-releases/teamchildren-and-the-andrew-hicks-foundation-donate-25-laptops-to-college-bound-chester-high-students-301071110.html
SOURCE TeamChildren
American Exchange Group partners with Sanrio® for new collection of Hello Kitty® smartwatches for kids
NEW YORK, June 4, 2020 /PRNewswire/ --Â American Exchange Group, in partnership with Sanrio, launches new children's smartwatch collection featuring various Hello Kitty prints for the 2020 Summer season under the iTOUCH Wearables PlayZoom brand.
The iTOUCH PlayZoom is a children's smartwatch that will feature special edition prints of the iconic Hello Kitty. The kid's smartwatch features fun learning games, a swivel camera for photos and videos including creative photo effects and custom Hello Kitty backgrounds, while interactively encouraging children to grow and develop independence with an alarm clock, stopwatch, timer, and voice recorder features. The iTOUCH PlayZoom allows kids to be engaged and safe without the use of GPS tracking or data connection and is perfect for children ages four and older. The iTOUCH PlayZoom is available at retailers nationwide including Macy's, JCPenney, and Kohl's with stock lists rapidly growing. The collection has a MSRP of $75.
About American Exchange Group
American Exchange Group is an industry leader in accessories design and manufacturing. By facilitating distribution to major retailers worldwide for custom private label brands, exclusive licensed brands, and branded accessories including watches, wearable technology, jewelry, footwear, and handbags American Exchange raises the bar by disrupting status quo pricing while staying at the forefront of trends.
About iTOUCH Wearables
iTOUCH Wearables is an affordable lifestyle tech brand that produces smartwatches, fitness trackers, kids smartwatches, portable speakers, earpods, and fashion-forward tech accessories. To learn more about iTOUCH Wearables, please visit www.itouchwearables.com and follow on Instagram, Facebook, Youtube and Pinterest and follow our PlayZoom brand on Instagram, Facebook, Youtube and Pinterest.
About Sanrio®
Sanrio, the global lifestyle brand best known for pop icon Hello Kitty®, and home to many other beloved character brands including Chococat™, My Melody™, Badtz-Maru™, Keroppi™, Gudetama™ and Aggretsuko™ is celebrating its 60th Anniversary this year. Sanrio was founded on the 'small gift, big smile®' philosophy – that a small gift can bring happiness and friendship to people of all ages. Since 1960, this philosophy has served as the inspiration to offer quality products, services and activities that inspire unique consumer experiences across the world. Today, Sanrio's legendary breadth of products are available in over 130 countries and in retail locations including department, specialty, national chain retailers and Sanrio boutique stores. To learn more about Sanrio, please visit www.sanrio.com and follow on Facebook, Instagram and Twitter.
View original content to download multimedia:http://www.prnewswire.com/news-releases/american-exchange-group-partners-with-sanrio-for-new-collection-of-hello-kitty-smartwatches-for-kids-301071105.html
SOURCE American Exchange Group
Dr. Kiran Mazumdar-Shaw from India named EY World Entrepreneur Of The Year(TM) 2020
LONDON, June 4, 2020 /PRNewswire/ --Â Dr. Kiran Mazumdar-Shaw, Executive Chairperson of India-based Biocon Limited, was this evening named EY World Entrepreneur Of The Yearâ„¢ 2020 at a ground-breaking, virtual award ceremony. Kiran was picked from among 46 award winners from 41 countries and territories vying for the world title. In the award's 20-year history, Kiran becomes the third EY World Entrepreneur Of The Year Award winner from India. She follows former Indian world title winners Uday Kotak of Kotak Mahindra Bank (2014) and Narayana Murthy of Infosys Technologies Limited (2005). She also becomes the second woman to hold the title, following Olivia Lum of Hyflux Limited from Singapore in 2011.
Kiran, 67, founded Biocon, a bio-enzymes company, in 1978 with just two employees and US$500. Since its inception, Biocon has grown to employ more than 11,000 people and become one of the strongest innovation-driven biotechnology companies in Asia with revenues of US$800m for FY19. Biocon and its subsidiaries are making a lasting impact on global health care. Millions of people living with diabetes now have access to affordable insulin, while millions more who are battling cancer, rheumatoid arthritis and other debilitating diseases now have access to affordable biosimilars.
Manny Stul, Chairman and Co-CEO of Moose Toys and Chair of the EY World Entrepreneur Of The Year judging panel, says:
"Kiran is an inspirational entrepreneur who demonstrates that determination, perseverance and a willingness to innovate can create long-term value. The judging panel were impressed by her ability to build and sustain growth over the past 30 years and by her integrity and passion for philanthropy that has delivered huge global impact. She has built India's largest biopharmaceutical company on a foundation of compassionate capitalism and putting patient needs before profits."
Dr. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, says:
"At its core, entrepreneurship is about solving problems. The greatest opportunities often arise at the toughest times, and that's been my experience throughout my entrepreneurial journey. My business focus is global health care and the provision of universal access to life saving medicine; however, my responsibility as an entrepreneur is greater than simply delivering value to shareholders. Wealth creation can be a catalyst for change, and all entrepreneurs have a responsibility to the world around them and the communities in which they operate. Women also play a hugely important role in economic development, and for too long their contribution has been ignored. It's important that we use the platform of EY World Entrepreneur Of The Year to encourage more women to participate in entrepreneurial pursuits. I'm truly honored to receive this prestigious award."
Carmine Di Sibio, EY Global Chairman and CEO, says:
"Entrepreneurs are the unstoppable visionaries who inspire innovation and fuel growth and prosperity by building remarkable companies and services. Kiran's passion to develop low-cost, cutting-edge pharmaceutical alternatives has brought affordable health care to patient communities all around the world. Her drive to innovate has created huge growth for Biocon Limited and helped diversify the company's portfolio of therapies for chronic diseases. Kiran is a truly inspiring EY World Entrepreneur Of The Year winner."
Stasia Mitchell, EY Global Entrepreneurship Leader, says:
"With an exceptional record in creating long-term value, Kiran's clear vision of making a difference to the lives of millions of people around the world make her a worthy EY World Entrepreneur Of The Year winner. Her impact on improving global health access and affordability will endure for decades to come. She is a beacon for other entrepreneurs to follow."
About Dr. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited
A first-generation entrepreneur, Kiran graduated as a Master Brewer from a brewing school in Australia and returned to her native India in 1975 to find work as a brew master. After two years of unsuccessfully trying to overcome the hurdles of entering a male-dominated brewing industry, Kiran started Biocon Limited, producing bio-industrial enzymes in the garage of her rented house in Bengaluru, India. A year later, Biocon became the first Indian company to export enzymes to the US and Europe.
Now, Biocon and its subsidiaries are the pioneers in areas less frequented by Indian pharmaceuticals companies, including fermentation-based small molecules, human insulin and insulin analogs, biosimilars for key antibody drugs, novel therapies, and high-end contract research services. With customers in over 120 countries, the company is a world leader in biosimilars and APIs for statins, immunosuppressants and other specialty molecules. In 2014, Biocon was India's first biotech company to go public and only the second Indian company to pass the US$1b mark on its first day of listing. The company's market capitalization is currently over US$4b.
Biocon is also leading the way on universal access to affordable life-saving medicine. For example, in September 2019, the company announced that it would supply rh-insulin at less than US$0.10 per day (for the average 40 units of insulin required per patient per day) to low- and middle-income countries — less than a third of current rh-insulin prices. The company has supplied more than 2 billion affordable doses of biosimilar insulins to patients globally in the last 15 years.
Compassionate capitalism that addresses inequality is at the center of Kiran's business and leadership philosophy. Founded in 2004, the Biocon Foundation provides basic health care, sanitation and early diagnosis and treatment of common cancers and non-communicable diseases to marginalized communities. Kiran has also been an angel investor for numerous successful health care startups in areas such as affordable breast cancer screening, chemotherapy determination, and low-cost warming devices for premature and low-birth-weight babies. The Mazumdar Shaw Center for Translational Research, a nonprofit research institute established by Kiran and dedicated to developing scientific breakthroughs for treating a wide range of human diseases, has also developed several advanced yet affordable cancer diagnostics. In 2016, Kiran signed The Giving Pledge, committing 75% of her wealth to philanthropy and giving back.
About the judging panel
The independent judging panel was chaired by Manny Stul, Chairman and Co-CEO of Moose Toys and EY World Entrepreneur Of The Year 2016 winner. Joining him were:
- Rosaleen Blair, CBE, Founder and Chair of Alexander Mann Solutions
- George Hongchoy, Executive Director and CEO of Link Asset Management Limited
- Hernan Kazah, Co-Founder and Managing Partner of Kaszek Ventures
- Sipho Nkosi, Chairman of Sasol
- Emine Sabancı Kamışlı, Co-Founder and Vice Chairperson of Esas Holding
Broadcast coverage and high-resolution content are available here for download for broadcast and online use.
Notes to Editors
About EY
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation is available via ey.com/privacy. For more information about our organization, please visit ey.com.
This news release has been issued by EYGM Limited, a member of the global EY organization that also does not provide any services to clients.
About EY Entrepreneur Of The Yearâ„¢
EY Entrepreneur Of The Yearâ„¢ is the world's most prestigious business awards program for unstoppable entrepreneurs. These visionary leaders deliver innovation, growth and prosperity that transform our world. The program engages entrepreneurs with insights and experiences that foster growth. It connects them with their peers to strengthen entrepreneurship around the world. EY Entrepreneur Of The Year is the first and only truly global awards program of its kind. It celebrates entrepreneurs through regional and national awards programs in more than 145 cities in over 60 countries. Winners go on to compete for the EY World Entrepreneur Of The Yearâ„¢ title. ey.com/eoy.
| Alan Duerden | Yvonne Diaz |
| EY Global Media Relations | EY Global Media Relations |
| +44 (0) 7392 106 100 | +44 (0) 7990 560 615 |
Â
View original content to download multimedia:http://www.prnewswire.com/news-releases/dr-kiran-mazumdar-shaw-from-india-named-ey-world-entrepreneur-of-the-year-2020-301071103.html
SOURCE EY
DLA Piper advises Iovance Biotherapeutics in its US$604 million common stock offering
NEW YORK, June 4, 2020 /PRNewswire/ -- DLA Piper represented Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), in a US$603.7 million underwritten public offering of 19,475,806 shares of its common stock at a public offering price of $31.00 per share, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance. The shares of common stock issued and sold in the offering include 2,540,322 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discounts and commissions.
Iovance plans to use the proceeds from the offering to fund the expansion of its organization to support the potential commercial launch of lifileucel for advanced melanoma and LN-145 for advanced cervical cancer, to initiate a program directed at registration of its tumor-infiltrating lymphocyte therapies in non-small cell lung cancer, to continue support of ongoing commercial manufacturing activities, and for the development of its IL-2 analog, IOV-3001, and for other general corporate purposes. Additional indications or TIL products may be explored with the use of proceeds.
"We are proud to have partnered with Iovance to complete this offering, applying our extensive experience advising life sciences, biotechnology and pharmaceutical clients in complex capital markets transactions. Over the last month, our East Coast life sciences team has closed public offerings for biotech companies in excess of $1 billion, and we are pleased to continue to support our clients' expansion and ongoing success," said Emilio Ragosa, the DLA Piper partner who led the firm's deal team.
In addition to Ragosa (Short Hills), the DLA Piper team advising Iovance included partners Patrick O'Malley and Neil Balmert (both of San Diego), as well as partners Rebecca McKnight (Austin) and Christopher Mikson (Philadelphia), and associates Oliver Newman, Dylan Caplan, David Pennant (all of Philadelphia), H. Thomas Felix, Nika Antonikova (both of San Diego) and Sarah Thompson Schick (Austin).
DLA Piper's global capital markets team represents issuers and underwriters in registered and unregistered  equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.
DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients' needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.
About DLA Piper
DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. In certain jurisdictions, this information may be considered attorney advertising. dlapiper.com
View original content:http://www.prnewswire.com/news-releases/dla-piper-advises-iovance-biotherapeutics-in-its-us604-million-common-stock-offering-301071099.html
SOURCE DLA Piper
Pond Technologies Holdings Inc. Announces Filing of 2019 Year-End Audited Financial Statements and MD&A
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS./
MARKHAM, ON, June 4, 2020 /CNW/ - Pond Technologies Holdings Inc. (the "Corporation" or "Pond")Â (TSXV: POND) (OTC: PNDHF)Â announces that the audited financial statements of the Corporation for the year ended December 31, 2019 and the related management's discussion and analysis have been filed and are available for review on the SEDAR website at www.sedar.com or on the Corporation's website at www.pondtech.com.
About Pond Technologies:
Located in Markham, Ontario, Pond is a technology company that provides profitable solutions to the global health and wellness challenges of climate change and nutrition. Pond's proprietary growth platform, including patented advanced photonics, optimizes key growth inputs in order to provide a controlled environment that maximizes the growth of algae and other organisms. This enables industrial emitters to generate new revenue streams from the transformation of underutilized CO2 to valuable algae-based products, such as protein for animal feed and nutraceutical products like Chlorella, Spirulina, and Astaxanthin for human consumption. For more information visit https://www.pondtech.com/.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Pond Technologies Holdings Inc.
The Province of Buenos Aires Extends Expiration of Invitation Memorandum (as defined below)
LA PLATA, Buenos Aires, Argentina, June 4, 2020 /PRNewswire/ -- The Province of Buenos Aires (the "Province") today announced that it has further extended the expiration of its invitation (the "Invitation") made to holders of certain eligible bonds (the "Eligible Bonds") listed in the Invitation Memorandum dated April 24, 2020 (as amended and supplemented from time to time, the "Invitation Memorandum") to submit orders to exchange their Eligible Bonds for new bonds pursuant to the terms and subject to the conditions described in the Invitation Memorandum from 5:00 p.m., Central European Time, on June 5, 2020, to 5:00 p.m., Central European Time, on June 19, 2020 (the "Expiration"), unless further extended or early terminated. Accordingly, assuming that the Province, among other things, does not further extend the Expiration or terminate the Invitation early, the Invitation Period (as defined in the Invitation Memorandum) is extended through the new Expiration, the Results Announcement Date (as defined in the Invitation Memorandum) shall be on June 22, 2020 or as early as practicable thereafter, and the Execution Date, the Effective Date and the Settlement Date, each as defined in the Invitation Memorandum, shall be on June 24, 2020 or as early as practicable thereafter.
The Province has engaged BofA Securities, Inc. and Citigroup Global Markets Inc. to act as dealer managers for the Invitation. D.F. King is acting as exchange, tabulation and information agent. Any questions or requests for assistance regarding the Invitation may be directed to BofA Securities, Inc. at +1 (888) 292-0070 (toll free) or +1 (646) 855-8988 (collect) or Citigroup Global Markets Inc. at +1 (800) 558-3745Â (toll free) and +1 (212) 723 6106Â (collect).
* * * * * * * * * *
Eligible Holders (as defined below), or custodians for such holders, of Eligible Bonds may obtain a copy of the Invitation Memorandum by contacting the dealer managers by calling any one of the numbers above or D.F. King at its email address (PBA@dfkingltd.com) or telephone number (+44 20 7920 9700 or +1 212-232-3233) or by download, following registration, via: https://sites.dfkingltd.com/PBA
Important Notice
This announcement is not an offer of securities for sale in the United States, and none of the New Securities (as defined in the Invitation Memorandum) has been or will be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and they may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. This press release does not constitute an offer of the New Securities for sale, or the solicitation of an offer to buy any securities, in any state or other jurisdiction in which any offer, solicitation or sale would be unlawful. Any person considering making an investment decision relating to any securities must inform itself independently based solely on an offering memorandum to be provided to eligible investors in the future in connection with any such securities before taking any such investment decision.
This announcement is directed only to beneficial owners of Eligible Bonds who are (A) "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act of 1933, as amended (the "Securities Act") or (B) (x) outside the United States as defined in Regulation S under the Securities Act, (y) if located within a Member State of the European Economic Area ("EEA") or the United Kingdom ("UK" and together with EEA each, a "Relevant State"), "qualified investors" as defined in Regulation (EU) 2017/1129 (as amended or superseded, the "Prospectus Regulation")Â and (z) if outside the EEA or the UK, is eligible to receive this offer under the laws of its jurisdiction (each an "Eligible Holder"). No offer of any kind is being made to any beneficial owner of Eligible Bonds who does not meet the above criteria or any other beneficial owner located in a jurisdiction where the Invitation is not permitted by law.
The distribution of materials relating to the Invitation may be restricted by law in certain jurisdictions. The Invitation is void in all jurisdictions where it is prohibited. If materials relating to the Invitation come into your possession, you are required by the Province to inform yourself of and to observe all of these restrictions. The materials relating to the Invitation, including this communication, do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. If a jurisdiction requires that the Invitation be made by a licensed broker or dealer and a dealer manager or any affiliate of a dealer manager is a licensed broker or dealer in that jurisdiction, the Invitation shall be deemed to be made by the dealer manager or such affiliate on behalf of the Province in that jurisdiction.
Forward-Looking Statements
All statements in this press release, other than statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, market conditions, and factors over which the Province has no control. The Province assumes no obligation to update these forward-looking statements, and does not intend to do so, unless otherwise required by law.
Notice to Investors in the European Economic Area and the United Kingdom
The New Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in a Relevant State. For these purposes, a "retail investor" means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); (ii) a customer within the meaning of Directive (EU) 2016/97 (as amended), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in the Prospectus Regulation. Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the New Securities or otherwise making them available to retail investors in a Relevant State has been prepared and therefore offering or selling the New Securities or otherwise making them available to any retail investor in a Relevant State may be unlawful under the PRIIPs Regulation. References to Regulations or Directives include, in relation to the UK, those Regulations or Directives as they form part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 or have been implemented in UK domestic law, as appropriate.
United Kingdom
For the purposes of section 21 of the Financial Services and Markets Act 2000, to the extent that this announcement constitutes an invitation or inducement to engage in investment activity, such communication falls within Article 34 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), being a non-real time communication communicated by and relating only to controlled investments issued, or to be issued, by the Province.
Other than with respect to distributions by the Province, this announcement is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Promotion Order, (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which the announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
View original content:http://www.prnewswire.com/news-releases/the-province-of-buenos-aires-extends-expiration-of-invitation-memorandum-as-defined-below-301071095.html
SOURCE The Province of Buenos Aires
Mountain Crest Acquisition Corp Announces Pricing of $50 Million Initial Public Offering
NEW YORK, June 4, 2020 /PRNewswire/ -- Mountain Crest Acquisition Corp (NASDAQ: MCACU, the "Company") announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The units are expected to be listed on The NASDAQ Capital Market ("NASDAQ") and trade under the ticker symbol "MCACU" beginning tomorrow, June 5, 2020. Each unit consists of one share of common stock and one right to receive one-tenth of one share of common stock upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the common stock and rights are expected to be listed on NASDAQ under the symbols "MCAC," and "MCACR," respectively.
The underwriters have been granted a 45-day option to purchase up to an additional 750,000 units offered by the Company to cover over-allotments, if any.
The offering is expected to close on June 9, 2020, subject to customary closing conditions.
Chardan acted as sole book running manager in the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 4, 2020. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Chardan Capital Markets, LLC, 17 State Street, 21st floor, New York, New York 10004. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Mountain Acquisition Corp
Mountain Crest Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Mountain Crest Acquisition Corp's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the Company intends to focus on operating businesses in North America.
Forward Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including the successful consummation of the Company's initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Mountain Crest Acquisition Corp
Dr. Suying Liu
Chairman and CEO
311 W 43rd St, 12th Fl, New York, NY 10036
(646) 493-6558
Â
View original content:http://www.prnewswire.com/news-releases/mountain-crest-acquisition-corp-announces-pricing-of-50-million-initial-public-offering-301071093.html
SOURCE Mountain Crest Acquisition Corp
Proof of Harm To CA's Unborn From Proximity To Oil Wells Proves Need For Barrier Between Wells And People, Says Consumer Watchdog
LOS ANGELES, June 4, 2020 /PRNewswire/ --Â The first definitive study showing perinatal harm from oil production in California to pregnant mothers proves that the state must institute a barrier of 2,500 feet between residents and oil wells and stop issuing new oil permits for wells within that zone, Consumer Watchdog said today.
Researchers at Berkeley's School of Public Health found that pregnant mothers living in rural locations within six tenths of a mile of the highest-producing oil wells in the state were 40% more likely to give birth to low weight babies and 20% more likely to have babies small for their gestational ages than people living further away. More than 5.4 million Californians live within one mile of a well.
"Such babies face higher risks of developmental and health problems throughout their lives and the communities affected are predominantly low-income communities of color with a long legacy of extractive and polluting industries," said Consumer Advocate Liza Tucker.
"They deserve environmental justice and what that means is instituting a barrier of at least 2,500 feet between people and oil production. Governor Newsom must also ban the issuing of any new oil permits to operate within that limit anywhere in the state."
For the Berkeley study, see:Â https://ehp.niehs.nih.gov/doi/full/10.1289/EHP5842
California has continued to issue new permits for oil and gas drilling since Newsom took office. The number of permits issued in 2019 rivaled the number that Governor Jerry Brown, a Big Oil booster, issued in 2018, his last year in office. In the first quarter of 2020, oil well permits rose 7.8% over the year before and California resumed issuing fracking permits after a nine-month moratorium.
About 12% of all permits issued in 2019 were for wells within 2,500 feet of homes, hospitals, schools, daycares and nursing facilities, according to FracTracker Alliance. In the first quarter, about 10% were issued within that range, exposing people to unacceptable levels of toxic and carcinogenic emissions.
People living near producing oil wells face elevated risks of cancer, respiratory and cardiovascular diseases in addition to reproductive harm. Â Studies in other states such as Colorado, Pennsylvania, Oklahoma, and Texas of the effects of hydraulic fracturing on people living nearby have also found low birth weights, preterm births and birth defects tied to proximity to oil production sites.
California is the only major oil-producing state besides Alaska that has no state setback whatsoever on proximity of oil wells to people.Â
There would be negligible effect on the oil industry and jobs if such a barrier were instituted, said Tucker. "The wells within 2500 feet of residents produce only 10% of the state's oil. Right now, oil production makes up only a few tenths of one percent of the state's GDP and of the state's private sector jobs. These workers could be put to work plugging up and cleaning up wells that currently threaten public health."
Â
View original content to download multimedia:http://www.prnewswire.com/news-releases/proof-of-harm-to-cas-unborn-from-proximity-to-oil-wells-proves-need-for-barrier-between-wells-and-people-says-consumer-watchdog-301071090.html
SOURCE Consumer Watchdog
Philadelphia Administrators' Union Protests Racial Injustice, Honors George Floyd With Silent March
PHILADELPHIA, June 4, 2020 /PRNewswire/ --Â Teamsters Local 502/Commonwealth Association of School Administrators (CASA) members joined with political, community and labor leaders today to protest the murder of George Floyd and denounce racial injustice and inequality.
Wearing masks and holding signs that read, "Gasping for Breath, Justice and Change," administrators, teachers, building engineers and other school workers, took part in a silent march from Local 502/CASA headquarters to the steps of the School District of Philadelphia headquarters, about a half-mile south from the union hall. Following the socially distanced march, the group knelt at the steps of the School District of Philadelphia for eight minutes and 46 seconds, the amount of time Floyd was pinned under a police officer's knee.
"As educational leaders at one of the largest school districts in the United States, with an overwhelmingly large population of students of color, it is imperative that we stamp out racism in all its forms, directly or indirectly. I want students and parents to know 'we hear you, and we are here for you.' We share your anger and understand the trauma that has affected families in Philadelphia and all across the country. We march today because our students' lives depend on it!" said Dr. Robin Cooper, President of Teamsters Local 502/CASA, amplifying the union's urgent call for the creation of a Diversity and Equity Office within the school district.
In addition to the establishment of a Diversity and Equity Office to address racism, Cooper also called on the school district to implement an "Inclusion of a Culturally Responsive Curriculum" to promote cultural differences in school programming.
"It is time for the school district to commit itself to new training programs to address racial issues. We will continue to promote anti-racist policies, cultural responsive curriculums, peaceful protests, and engage in intellectual discourse and courageous conversations on difficult topics such as racism," Cooper said.
Following the march and action on the steps of the school district office, CASA members held a press conference with union leaders and members from the Philadelphia Federation of Teachers and SEIU Local 32BJ, as well as many supporters in the community, including political and community leaders.
Teamsters Local 502/CASA represents approximately 700 school administrators who work in the School District of Philadelphia as principals, assistant principals, facilities area coordinators, climate managers and school police, food service supervisors, early childhood supervisors, leadership coaches and curriculum specialists.
Contact:
Dr. Robin Cooper, (215) 205-5147
casapresident502@gmail.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/philadelphia-administrators-union-protests-racial-injustice-honors-george-floyd-with-silent-march-301071089.html
SOURCE Teamsters Local 502
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds iAnthus Capital Holdings, Inc. Investors to Contact Firm Before June 15 Deadline in Class Action Seeking Recovery of Investor Losses - ITHUF
NEW YORK, June 4, 2020 /PRNewswire/ --Â Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of iAnthus Capital Holdings, Inc. (OTC: ITHUF) between May 14, 2018 and April 6, 2020, inclusive (the "Class Period") of the important June 15, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for iAnthus investors under the federal securities laws.
To join the iAnthus class action, go to http://www.rosenlegal.com/cases-register-1855.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.
According to the lawsuit, defendants made materially false and misleading statements regarding iAnthus's business, operational, and compliance policies. Specifically, defendants issued a series of statements representing that iAnthus's business operations, financed through various debt and equity offerings, were expanding throughout the United States, without disclosing to shareholders that defendants were either unwilling or unable to utilize escrowed funds to make necessary interest payments under certain of iAnthus's debenture agreements. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 15, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1855.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     lrosen@rosenlegal.com
     pkim@rosenlegal.com
     cases@rosenlegal.com
     www.rosenlegal.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-longstanding-and-trusted-firm-reminds-ianthus-capital-holdings-inc-investors-to-contact-firm-before-june-15-deadline-in-class-action-seeking-recovery-of-investor-losses--ithuf-301071062.html
SOURCE Rosen Law Firm, P.A.
XLCS Partners advises Nortech Packaging and Tishma Technologies in sale to Intertape Polymer Group
CHICAGO, June 4, 2020 /PRNewswire/ --Â XLCS Partners, Inc., a leading middle market investment bank, is pleased to announce it served as exclusive advisor to Nortech Packaging and Tishma Technologies in sale to Intertape Polymer Group Inc. (IPG). Â
Schaumburg, Illinois based Nortech manufactures, assembles and services automated packaging machines under the Nortech Packaging and Tishma Technologies brands. Its custom-infeed and robotic solutions for packaging applications are designed for cartoning, case-packing, case-erecting, pouch-packaging and palletizing. Founded in 2001, the Company services customers worldwide across major industries including food, pharmaceutical, e-commerce, confections, personal care and cosmetics, and beverage.
IPG (TSX:ITP) is a recognized leader in the development, manufacture and sale of a variety of paper- and film- based pressure sensitive and water-activated tapes, polyethylene and specialized polyolefin films, protective packaging, woven coated fabrics and complementary packaging systems for industrial and retail use. Headquartered in Montreal, Quebec and Sarasota, Florida, IPG employs approximately 3,600 employees with operations in 30 locations, including 21 manufacturing facilities in North America, four in Asia and one in Europe.
The acquisition will expand IPG's product bundle into technologies that are increasingly critical to automation in packaging. With an installed fleet of more than 400 machines, the acquisition provides IPG with opportunities to supply consumables to the existing fleet, as well as deploy system-selling for new customers combining machines with ongoing consumables. The acquisition will add engineering automation and integrated robotic design talent to IPG's existing engineering and design teams. Upon closing, IPG expects these new capabilities will allow it to service customers experiencing growth pressures that require a customized automation solution.
"Anthony's in-depth understanding of our business combined with the firm's streamlined process, marketing efforts, and packaging sector knowledge produced excellent results," said David Showman, Nortech Packaging and Tishma Technologies President. "We are very excited about the future and greatly appreciate the guidance and hard work of the XLCS team."
XLCS acted as the exclusive M&A advisor to Nortech Packaging and Tishma Technologies and the transaction was led by Anthony Contaldo, Partner and Head of XLCS's Packaging Industry Practice Group. The transaction was completed on February 11, 2020.
About XLCS Partners, Inc.
XLCS Partners is an investment banking firm providing M&A advisory services to select clients globally. More information is available at www.xlcspartners.com.
Contact: Kendra Span, 847-836-7036, kspan@xlcspartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/xlcs-partners-advises-nortech-packaging-and-tishma-technologies-in-sale-to-intertape-polymer-group-301071087.html
SOURCE XLCS Partners, Inc.
